Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest Update

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the target of a large decline in short interest in June. As of June 15th, there was short interest totaling 15,577 shares, a decline of 51.9% from the May 31st total of 32,362 shares. Based on an average trading volume of 23,991 shares, the short-interest ratio is currently 0.6 days. Approximately 2.8% of the shares of the stock are short sold.

Sigyn Therapeutics Stock Up 4.9%

OTCMKTS SIGY opened at $0.04 on Thursday. Sigyn Therapeutics has a twelve month low of $0.01 and a twelve month high of $5.00. The stock has a market cap of $93,218.00, a P/E ratio of -0.01 and a beta of -0.08. The company’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.42.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.